Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors

BMC Pulmonary Medicine

Concepción Montón⁵  Eduard Monsó⁶  David Suárez⁴  Mar Solé¹  Eva Castañer²  Mateu Espasa³  Xavier Pomares⁵  Miguel Gallego⁶ 

[1] Barcelona Centre for International Health Research (CRESIB), Department of Clinical Microbiology, Hospital Clínic-Fundació Clínic per la Recerca Biomèdica, University of Barcelona, Barcelona, Spain;Department of Radiology, SDI UDIAT, Institut Universitari Parc Taulí-UAB;Department of Microbiology, SDI UDIAT, Institut Universitari Parc Taulí-UAB, Sabadell, Spain;Epidemiology and Assessment Unit, Fundació Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain;Department of Respiratory Medicine, Hospital de Sabadell, Institut Universitari Parc Taulí-UAB, Sabadell, Spain;CIBER de Enfermedades Respiratorias, CIBERES, Bunyola, Spain

关键词: Pseudomonas aeruginosa;    Chronic colonization;    Bronchiectasis;    Chronic obstructive pulmonary disease;   

Others  :  862775
DOI  :  10.1186/1471-2466-14-103

 received in 2014-03-28, accepted in 2014-06-19,  发布年份 2014

【 摘 要 】

Background

Patients with severe chronic obstructive pulmonary disease (COPD) are at increased risk of infection by P. aeruginosa. The specific role of bronchiectasis in both infection and chronic colonization by this microorganism in COPD, however, remains ill defined.

To evaluate the prevalence and risk factors for P. aeruginosa recovery from sputum in outpatients with severe COPD, characterizing P. aeruginosa isolates by pulsed-field gel electrophoresis (PFGE) and focusing on the influence of bronchiectasis on chronic colonization in these patients.

Methods

A case-cohort study of 118 patients with severe COPD attended at a Respiratory Day Unit for an acute infectious exacerbation and followed up over one year. High-resolution CT scans were performed during stability for bronchiectasis assessment and sputum cultures were obtained during exacerbation and stability in all patients. P. aeruginosa isolates were genotyped by PFGE. Determinants of the recovery of P. aeruginosa in sputum and chronic colonization by this microorganism were assessed by multivariate analysis.

Results

P. aeruginosa was isolated from 41 of the 118 patients studied (34.7%). Five of these 41 patients (12.2%) with P. aeruginosa recovery fulfilled criteria for chronic colonization. In the multivariate analysis, the extent of bronchiectasis (OR 9.8, 95% CI: 1.7 to 54.8) and the number of antibiotic courses (OR 1.7, 95% CI: 1.1 to 2.5) were independently associated with an increased risk of P. aeruginosa isolation. Chronic colonization was unrelated to the presence of bronchiectasis (p=0.75). In patients with chronic colonization the isolates of P. aeruginosa retrieved corresponded to the same clones during the follow-up, and most of the multidrug resistant isolates (19/21) were harbored by these patients.

Conclusions

The main risk factors for P. aeruginosa isolation in severe COPD were the extent of bronchiectasis and exposure to antibiotics. Over 10% of these patients fulfilled criteria for chronic colonization by P. aeruginosa and showed clonal persistence, independently of the presence of bronchiectasis.

【 授权许可】

   
2014 Gallego et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365.
• [2]Moreno C, Montón Y, Belmonte M, Gallego X, Pomares X, Real J: Causas de muerte en pacientes con EPOC grave. Factores pronósticos. Arch Bronconeumol 2009, 45:181-186.
• [3]Murphy TF: Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009, 15:138-142.
• [4]Eller J, Ede A, Schaberg T, Niederman M, Mauch H, Lode H: Infective exacerbation of chronic bronchitis. Relation between bacteriologic etiology and lung function. Chest 1998, 113:1542-1548.
• [5]Miravitlles M, Espinosa C, Fernández-Laso E, Martos JA, Maldonado JA, Gallego M, and study group of bacterial infection in COPD: Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999, 116:40-46.
• [6]Monsó E, Garcia-Aymerich J, Soler N, Farrero E, Felez MA, Antó JM, Torres A, EFRAM Investigators: Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect. 2003, 131(1):799-804.
• [7]Lode H, Allewelt M, Balk S, De Roux A, Mauch H, Niederman M, Schmidt-Ioanas M: A prediction model for bacterial etiology in Acute Exacerbations of COPD. Infection 2007, 35:143-149.
• [8]García-Vidal C, Almagro P, Romaní V, Rodríguez-Carballeira M, Cuchi E, Canales L, Blasco D, Heredia JL, Garau J: Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009, 34:1072-1078.
• [9]Renom F, Yáñez A, Garau M, Rubí M, Centeno MJ, Gorriz MT, Medinas M, Ramis F, Soriano JB, Agustí A: Prognosis of COPD patients requiring frequent hospitalization: Role of airway infection. Respir Med 2010, 104:840-848.
• [10]Martínez-García MA, Soler-Cataluña JJ, Donat Y, Catalán P, Agramunt M, Ballestín J, Perpiñá-Tordera M: Factors associated with bronchiectasis in patients with COPD. Chest 2011, 140:1130-1137.
• [11]Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Torres A, van der Heijden G, Read R, Verheij TJ, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases: Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011, 17(Suppl. 6):E1-E59.
• [12]From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/ webcite
• [13]Rakhimova E, Wiehlmann L, Brauer AL, Sethi S, Murphy TF, Tümmler B: Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. J Infect Dis 2009, 200:1928-1935.
• [14]Martínez-Solano L, Macia MD, Fajardo A, Oliver A, Martínez JL: Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008, 47:1526-1533.
• [15]Valderrey AD, Pozuelo MJ, Jiménez PA, Maciá MD, Oliver A, Rotger R: Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung disease: cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis 2010, 68:20-27.
• [16]Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
• [17]Celli BR, Cote CG, Marín JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ: The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
• [18]Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47:1245-1251.
• [19]Pomares X, Monton C: Respiratory day hospital: what have we learned? Med Clin (Barc) 2011, 136:454-455.
• [20]Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E, Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient: Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005, 11(9):690-703.
• [21]Patel IS, Vlahos I, Wilkinson TMA, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA: Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:400-407.
• [22]Lynch DA, Newell JD, Tschomper BA, Cink TM, Newman LS, Bethel R: Uncomplicated asthma in adults: comparison of CT appearances of the lungs in asthma and in healthy subjects. Radiology 1993, 188:829-833.
• [23]Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson J, Flower CDR: Chronic sputum production: correlation between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax 1996, 51:914-918.
• [24]Murray PR, Washington JA: Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin Proc 1975, 50(6):339-344.
• [25]Begoña Cacho J, Meseguer MA, Oliver A, Puig J: Diagnóstico Microbiológico de las Infecciones Bacterianas del tracto Respiratorio Inferior. Madrid: SEIMC; 2007.
• [26]Cabello H, Torres A, Celis R, El-Ebiary M, Puig de la Bellacasa J, Xaubet A, González J, Agustí C, Soler N: Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997, 10(5):1137-1144.
• [27]National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing. Wayne: National Committee for Clinical Laboratory Standards; 2004:M100-S114.
• [28]Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281.
• [29]Durmaz R, Otlu B, Koksal F, Hosoglu S, Ozturk R, Ersoy Y, Aktas E, Gursoy NC, Caliskan A: The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis 2009, 62:372-377.
• [30]Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S: Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:853-860.
• [31]Martínez-García MA, de la Rosa D, Soler-Cataluña JJ, Donat-Sanz Y, Catalán P, Agramunt M, Ballestín J, Valero I, Selma MJ, Roma A, Bertomeu M: Prognostic value of bronchiectasis in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 187:823-831.
• [32]Almagro P, Salvadó M, García-Vidal C, Rodríguez-Carballeira M, Cuchi E, Torres J, Heredia J: Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012, 84:36-43.
• [33]Foweraker JE, Laughton CR, Brown DF, Bilton D: Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother 2005, 55(6):921-927.
• [34]Hogardt M, Heesemann J: Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr Top Microbiol Immunol 2013, 358:91-118.
• [35]Novosad SA, Barker AF: Chronic obstructive pulmonary disease and bronchiectasis. Curr Opin Pulm Med 2013, 19(2):133-139.